GE Healthcare
This sponsor has funded 3 studies across 13 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 21473 | Ongoing | A study of pattern of use for gadolinium-based contrast agents (GBCAs) in patients undergoing contrast-enhanced magnetic resonance (CE-MR) examination... | Yes | No |
| 24735 | Finalised | A Post-Authorisation Safety Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training in Europe | Yes | No |
| 25167 | Finalised | Post-Authorisation Survey of Nuclear Medicine Physicians and Radiologists in Europe to Evaluate Trends and Patterns in VIZAMYL™ Use in Everyday... | Yes | No |
PAS by Risk Management Plan (RMP) requirement
GE Healthcare
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
GE Healthcare
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
GE Healthcare
13 Study countries specified are the following:
- Austria
- Belgium
- Finland
- France
- Germany
- Italy
- Netherlands
- Norway
- Poland
- Portugal
- Slovakia
- Spain
- Sweden